China
Africa
Explore chapters and articles related to this topic
Main Classes of Drugs
Published in Jerome Z. Litt, Neil H. Shear, Litt's Drug Eruption & Reaction Manual, 2017
CNS stimulantCocaineDexmethylphenidateDextroamphetamineLisdexamfetamineModafinil
Treatment characteristics among patients with binge-eating disorder: an electronic health records analysis
Published in Postgraduate Medicine, 2023
William M. Spalding, Monica L. Bertoia, Cynthia M. Bulik, John D. Seeger
These analyses report demographic characteristics, lifestyle characteristics, and comorbidities during the 12-month baseline period preceding BED recognition for all study cohorts. Treatment characteristics during the 12-month baseline period preceding BED recognition and during the follow-up period are reported. The follow-up period included the time from BED recognition until departure from the provider group or end of follow-up (30 September 2015). Operational definitions of demographics, lifestyle characteristics, and comorbidities are included in Supplementary Table 1. Receipt of prescriptions for pharmacotherapy was identified using drug class and generic name; receipt of/discussions about psychotherapy were identified using NLP terms. NLP terms for concepts related to CBT and other general types of therapy terms were identified and grouped into the following categories: CBT, behavior therapy, nonspecific therapy, group therapy, and family therapy. Using concept modifiers, patients with affirmations of these flags were further classified as having ‘received’ versus ‘discussed’ psychotherapy. A post hoc analysis was conducted to determine the number of patients who received a first prescription for lisdexamfetamine before and after the date of approval by the FDA for the treatment of BED, stratified by presence or absence of comorbid attention-deficit/hyperactivity disorder (ADHD) at baseline.
Anodal Contralesional tDCS Enhances CST Excitability Bilaterally in an Adolescent with Hemiparetic Cerebral Palsy: A Brief Report
Published in Developmental Neurorehabilitation, 2023
Rodrigo G. Delatorre, Ellen N. Sutter, Samuel T. Nemanich, Linda E. Krach, Gregg Meekins, Timothy Feyma, Bernadette T. Gillick
The participant was a 14-year-old male with a history of perinatal stroke who subsequently developed spastic hemiparesis affecting the right side. His Manual Ability Classification System (MACS) level was III (“handles objects with difficulty; needs help to prepare and/or modify activities”). The participant’s structural MRI revealed cystic degeneration and significant volume loss of the left frontoparietal lobes and subcortical parenchyma, as well as dilation of the left lateral ventricle and midline shift to the left due to volume loss, consistent with an in-utero infarct of the left middle cerebral artery (Figure 1). He had no history of seizure, or of cardiac, pulmonary, GI, or renal impairment. Medications included 10 mg Lisdexamfetamine Dimesylate (Vyvanse) taken once per day in the morning.
Toxicity of acute exploratory amphetamine-salt medication in amphetamine-naïve pediatrics: a retrospective cohort study
Published in Clinical Toxicology, 2020
James B. Leonard, Amy Kruger Howard, Elizabeth Q. Hines
Cases were included if they were acute, single-substance exposures to a non-illicit amphetamine salt in the defined age criteria. Cases were excluded if the exposure was to other amphetamines (e.g., phentermine, methamphetamine), the exposure was to lisdexamfetamine, the exposure was acute-on-chronic, the patient was non-naïve to stimulants, if the patient was not followed to a known final outcome, the dose was unavailable, or the weight was unknown. Cases were identified using the generic code for amphetamine according to Poisindex (001000). Acute-on-chronic ingestions were defined as a patient taking a higher-than-normal dose for a medication they use chronically. Acute-on-chronic exposures were excluded because prior development of tolerance might falsely increase the median dose of those patients who were asymptomatic and untreated. Lisdexamfetamine is a pro-drug of dextroamphetamine with a delayed time to peak of approximately 3.5 h. One study published in abstract recommends a triage dose of 3 mg/kg and the toxicity seems to differ from the classic amphetamines used for treatment of ADHD [9].